Financial Report: Amgen

Amgen

4Q Revenues: $3.8 billion (+1%)

4Q Earnings: $1.0 billion (+10%)

FY Revenues: $15.1 billion (+3%)

FY Earnings: $4.6 billion (flat)

Comments: U.S. product sales were flat at $2.9 billion in the quarter and included a $65 million unfavorable impact due to U.S. health care reform. International product sales were up 3% to $891 million. Total product sales included a $26 million negative impact of foreign exchange. For the year, U.S. product sales increased 1% to $11.3 billion and included a $198 million unfavorable impact due to U.S. health care reform. International product sales were up 6% to $3.4 billion. Worldwide Aranesp sales were down 2% to $633 million in the quarter and down 6% to $2.5 billion for the year. Sales of Epogen were $591 million in the quarter (-16%), and decreased 2% to $2.5 billion for the year. Combined worldwide Neulasta and Neupogen sales were up 3% to $1.2 billion in the quarter, and up 4% to $4.8 billion for the year. Enbrel sales were $939 million in the quarter (+3%) and $3.5 billion for the year (+1%).